Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial

Does colchicine added to standard medical therapy reduce major adverse cardiac events in patients with acute coronary syndrome?

Adding colchicine to standard medical therapy in ACS patients significantly reduces MACE and improves survival over a 6-month period.